Clinical-stage biopharmaceutical leader Radiopharm Theranostics (ASX:RAD) has released its financial results for the first half of fiscal 2026, reporting a cash position of $34.5 million and a series of significant clinical breakthroughs.
Under the leadership of CEO Riccardo Canevari, the company spent 2025 accelerating its "theranostic" pipeline—a strategy that combines diagnostic imaging with targeted radiotherapy—advancing multiple oncology programs into critical Phase 1 and 2 stages.
A primary highlight is the 18F-RAD101 program, a small molecule diagnostic targeting brain metastases.
Recent interim Phase 2b data showed a 92% concordance rate with MRI imaging, positioning the company to initiate a Phase 3 registrational trial later this year.
Additionally, the company is preparing to dose the first patients in its RV 01 Phase 1 trial—a monoclonal antibody developed in partnership with MD Anderson Cancer Center—following an increase in its ownership of the Radiopharm Ventures joint venture to 87.5%.
Radiopharm is also seeing momentum in its therapeutic assets. The RAD 202 program, targeting HER2-positive solid tumours, and RAD 204, targeting PD-L1-driven lung cancers, both received safety clearance to escalate dosing after showing favourable safety profiles and encouraging tumour uptake.
The company expanded its footprint in prostate cancer treatment with the upcoming Phase 1 launch of RAD 402, a novel antibody labeled with Terbium-161.